ArticleAlzheimer's & dementia (New York, N. Y.)2019
Alzheimer's Prevention Initiative Generation Program: Development of an
Article in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- CONNECT4 APOE: A randomized trial of telephone versus real-time two-way videoconference for disclosure of APOE genotype results in cognitively unimpaired adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Tele-Genetic Versus Onsite Counseling for APOE Disclosure: A 6-Month Study of Empowerment, Psychological Distress, and Behavioral Outcomes in Cognitively Diverse Individuals.The journal of gene medicine · 2025Trial
- Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Trial
- The ENGAGE study: a 3-arm randomized hybrid type 1 effectiveness and implementation study of an in-home, collaborative PCP model of remote telegenetic services to increase uptake of cancer genetic services in childhood cancer survivors.BMC health services research · 2024Trial
- Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.The journal of prevention of Alzheimer's disease · 2023Trial
- Reciprocity in research: Participant views on return of results in the WATCH-PD qualitative study.Journal of Parkinson's disease · 2026Article
- Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma.Psychology and aging · 2026Article
- An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Supporting frontline staff in frontotemporal degeneration research.Frontiers in neurology · 2026Article
- Disclosure of onset-predictive biomarker results to research participants at risk of genetic frontotemporal dementia: a European perspective.Alzheimer's research & therapy · 2025Review
- Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1.The lancet. Healthy longevity · 2025Article
- Communicating the risk of dementia: a scoping review.BMJ neurology open · 2025Article
- Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Advertisement by medical facilities as an opportunity route of APOE genetic testing in Japan: a website analysis.Journal of community genetics · 2024Article
- Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study.Alzheimer's research & therapy · 2024Article
- Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- User and Usability Testing of a Web-Based Genetics Education Tool for Parkinson Disease: Mixed Methods Study.JMIR bioinformatics and biotechnology · 2023Article
- Comprehensive genetic screening of early-onset dementia patients in an Austrian cohort-suggesting new disease-contributing genes.Human genomics · 2023Article
- Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individuals-From Current Practice towards a Personalised Medicine Scenario.Biomedicines · 2022Review
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
Abstract
introductionAs the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E (
methodsA multidisciplinary Genetic Testing, Counseling, and Disclosure Committee was established and charged with operationalizing the Alzheimer's Prevention Initiative (API) Genetic Counseling and Disclosure Process for use in the API Generation Program trials. The objective was to provide consistent information to research participants before and during the
resultsThe Genetic Testing, Counseling, and Disclosure Committee created a process consisting of eight components: requirements of DISCUSSION: The API Genetic Counseling and Disclosure Process provides a framework for large-scale disclosure of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.